April 29, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.04.011

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Listen to this summary

The authors aimed to investigate whether patient demographic factors, such as age, race, and ethnicity, are associated with real-world outcomes of antibody-drug conjugates (ADCs) in patients with advanced gynecologic cancers. Their study found that while overall survival (OS) and progression-free survival (PFS) varied by ethnicity and performance status in unadjusted analyses, these differences were not significant after multivariable adjustment, suggesting that real-world ADC outcomes align with pivotal trial results and highlighting the need for further exploration of factors influencing treatment efficacy.

Eliya K Shachar, Jordyn Silverstein, Lorna Kwan, Ritu Salani, Beth Y Karlan, Dana M Chase

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play